{"id":740110,"date":"2023-03-14T18:25:00","date_gmt":"2023-03-14T22:25:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/"},"modified":"2023-03-14T18:25:00","modified_gmt":"2023-03-14T22:25:00","slug":"harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/","title":{"rendered":"Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">\n          <em>Preclinical abstracts for investigational T cell engagers, HPN328 and HPN217, in mouse models provide further validation of Harpoon\u2019s proprietary Tri-specific T cell Activating Construct (TriTAC<\/em><br \/>\n          <sup><br \/>\n            <em>\u00ae<\/em><br \/>\n          <\/sup><br \/>\n          <em>) platform and support ongoing clinical efforts<\/em><br \/>\n          \n        <\/li>\n<li>\n          <em>Additional abstracts support further investigation of Harpoon\u2019s conditionally active next-generation T cell engager platform, ProTriTAC\u2122, with demonstrated therapeutic potential in a broad range of TROP2- and ITGB6-expressing solid tumors<\/em>\n        <\/li>\n<\/ul>\n<p>SOUTH SAN FRANCISCO, Calif., March  14, 2023  (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc.\u00a0(Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that it will present data from five preclinical investigations in poster presentations at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Fla., April 14-19, 2023.<\/p>\n<p>\u201cThe breadth of data from Harpoon\u2019s five poster presentations at AACR supports further investigation of additional tumor targets, combination approaches with TriTACs<sup>\u00ae<\/sup>, as well as our next-generation technology platform with conditionally active T cell engager prodrugs, or ProTriTACs\u2122,\u201d said Julie Eastland, President and Chief Executive Officer of Harpoon Therapeutics. \u201cAdditionally, the preclinical data investigating the activity of TriTAC in an immunocompetent mouse model provide further validation of our ongoing and planned clinical efforts with HPN328 and HPN217, leveraging our proprietary TriTAC T cell engager platform. We look forward to further validation in the clinic as our research efforts continue.\u201d<\/p>\n<p>Details of the AACR poster presentations are as follows:<\/p>\n<p>\n        <strong>Title:\u00a0<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RMSYKEbfQIByawY-BxcQDV0QP4fGR9XktiCGJTu-OruGruwTB32huCf6wn49TdQ6Tak1yK8DxkgnRT8iIg1KKY8Lc-WlsiexmkD_QU_xN0hcIwFrMsJf2IXvXUdwTGH3GUOf4jKQ117fUaHt1PuTBfief9U3zlakIbNSDRUyaPGWUXRNsRWqs5_JeidJC1J_5mzjpZ4b6RQA9H9FbAYnUSrsb3dIdB-3KY0I2DECTqnXkwzndnxFM8vbLENlhhl5mql7bD6x7FvVQQXmN70aHhFmL3GpI0uR4NgIdF6esn5ZI5glTueGBcTtmHsTPDYJG0IUmJDCOYOg0K0EMXrnAA==\" rel=\"nofollow noopener\" target=\"_blank\">Long-term anti-tumor immunity induced by HPN328, a DLL3-targeting tri-specific, half-life extended T cell engager, in a preclinical immunocompetent mouse model<\/a><br \/>\n        <br \/>\n        <strong>Abstract Number: <\/strong>4131<br \/><strong>Session: <\/strong>Immunology\/Determinants of Immunotherapeutic Effectiveness<br \/><strong>Session Date, Time: <\/strong>Tuesday, April 18, 9 a.m. &#8211; 12:30 p.m. ET<br \/><strong>Location:<\/strong> Poster Section 24<\/p>\n<p>\n        <strong>Title:\u00a0<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WkGmkMslc4ae7Iuy93hSq0eEmcVEyat9dLZYDbtZOxWrQoiuF3_5qksBc_S7k8-1IZdmOFUDXKU_PZ6UmBYMEl1WKHMKbAfXNKKelNOIRTnrEPbsWfv7iB2wOeqNC-4Yyf2M4k8bMd-x3tbATewWxEKhmM2RgNYxhiSjWWrq9R8XRsqNnujpHiFnPCkCS9btnr3Rr6wI1jlt3dEFSCZEt5sYPrv11_D_D9B8lRFbUOn-hXJxsB3ZWiqvga6q1GiSiTPbRAVlkBk7H2YOzU1auiZ-LAVIDdAfL9kAFSwtHmL2okwRLg-lb9HckGt6c7TFk3jBYjrttsVYVi6rtGkGjhJSJTro_0FJTzurH4kq18A=\" rel=\"nofollow noopener\" target=\"_blank\">Anti-tumor activity of HPN328, a DLL3-targeting tri-specific, half-life extended T cell engager, is enhanced by combining with an anti-PD-L1 antibody in an immunocompetent mouse model<\/a><br \/>\n        <br \/>\n        <strong>Abstract Number: <\/strong>5070<br \/><strong>Session: <\/strong>Immunology\/Combination Immunotherapies 1<br \/><strong>Session Date, Time: <\/strong>Tuesday April 18, 1:30 &#8211; 5 p.m. ET<br \/><strong>Location:<\/strong> Poster Section 21<\/p>\n<p>\n        <strong>Title:\u00a0<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WkGmkMslc4ae7Iuy93hSq0eEmcVEyat9dLZYDbtZOxWvanCH5MbYx8u3Cjrr2qad46g8brd481DB1LYEtYAfANy8Fwy-MOO8jdu6QCbDNb2DkLtqJOAFzhtLcvOkl5C43gIk0Wu4sd1vCYdzHeSjWSBH--2ViXq2tUfAuteAofrJEG9pD8u8Y2Nduo4oDoItJXC0TTtezSDZ6o_gTUc6y-5uei2ohY6qaevttt_9KEIk5VQNfzcxwkJTMF79SdryJ3_cA1sUW6RPAOuJI0V7bhmNZ0SRaU66yUDBvPez15E=\" rel=\"nofollow noopener\" target=\"_blank\">Anti-tumor activity of HPN217, a BCMA-targeting tri-specific T cell engager, is enhanced by \u03b3-secretase inhibitors in preclinical models<\/a><br \/>\n        <br \/>\n        <strong>Abstract Number: <\/strong>5081<br \/><strong>Session: <\/strong>Immunology\/Combination Immunotherapies 1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/><strong>Session Date, Time: <\/strong>Tuesday April 18, 1:30 &#8211; 5 p.m. ET<br \/><strong>Location:<\/strong> Poster Section 21<\/p>\n<p>\n        <strong>Title:\u00a0<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vvXdYugCUBzDbMF-hdq91QpbkyGDZ2geJHpwfz2lwoGsLlfF9H8jyWtounnLn0M_v5Yx5VmA0tUsssy6rzsF9vFmezO9Kjig4QBdH4542K0CS8IG3-hmG6HMJiq7H168aoY8N-Pz3LhVbu9H3zZuGOgVLocpD3hD1xubUfW9jDlnxZJetaQBe9P8IdqYP_KLWGdgAJ74HJttpttlGVy_ZGoMz_IFUgPx-D-v4t7bV5AVfZZrMJfbQkE_w-YKCH6j8RGBlvNKSvMx1RNxqB52IQ==\" rel=\"nofollow noopener\" target=\"_blank\">TROP2 ProTriTAC\u2122, a protease-activated T cell engager prodrug targeting TROP2 for the treatment of solid tumors<\/a><br \/>\n        <br \/>\n        <strong>Abstract Number: <\/strong>2928<br \/><strong>Session: <\/strong>Immunology\/Therapeutic Antibodies 2<br \/><strong>Session Date, Time: <\/strong>Monday April 17, 1:30 &#8211; 5 p.m. ET<br \/><strong>Location:<\/strong> Poster Section 23<\/p>\n<p>\n        <strong>Title:\u00a0<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GCDsIRv1q8pmUrHmsgpqzWN9PppkClYqOTW31eWC9LlHXiaTDqXh0ZvtU34TosgRqCkh-HaiBhz-J-_qt3uGKVPnVslKxygTPiruiJbe6Gg4IPNUpJlT7pqkbDZSDs3X1Y5kS5zKthNwuO8xb2J-EC0o4xLxX6il8BF45Ubtlf98zU39poBnjXTsh0PEUMsdVNg2sPspZzUaAF4nmpu7HoViHZLQ6oLhyAlNkkUCMZfl_4BKE-hRli2bERQKmJO_Hk0YQus5sjO1fjdWRS55BQ==\" rel=\"nofollow noopener\" target=\"_blank\">ITGB6 ProTriTAC\u2122, a protease-activated T cell engager prodrug targeting Integrin-\u03b26 for the treatment of solid tumors<\/a><br \/>\n        <br \/>\n        <strong>Abstract Number: <\/strong>2927<br \/><strong>Session: <\/strong>Immunology\/Therapeutic Antibodies 2<br \/><strong>Session Date, Time: <\/strong>Monday April 17, 1:30 &#8211; 5 p.m. ET<br \/><strong>Location:<\/strong> Poster Section 23<\/p>\n<p>The posters will also be available on Harpoon\u2019s website following the presentations.<\/p>\n<p>For more details about the AACR Annual Meeting, please visit: <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BQsxoqyhVhG_oCkIZIoZ4mJCtMj92LNqMKmcpIE067-x23YGa8SHewzCKI0LkA65-w2JHpJz9QV_LyOUmvCh4EeQp-FXDzBkn_r727Eia3rZ4coEapjuq0rJH9cQuKDjs-0JLrp83g1OlBh_ihCWZ21oWNKdMPQNVlfrJ2yIM_fsyf8HHce0AiBTMVrciQfC\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.aacr.org\/meeting\/aacr-annual-meeting-2023\/<\/a><\/p>\n<p>\n        <strong>About Harpoon Therapeutics <\/strong>\n      <\/p>\n<p>Harpoon Therapeutics\u00a0is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body\u2019s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient\u2019s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC<sup>\u00ae<\/sup>) platform, Harpoon is developing a pipeline of novel TriTACs\u00a0initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC\u2122\u00a0platform, which applies a prodrug concept to its TriTAC\u00a0platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon\u2019s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. For additional information about Harpoon Therapeutics, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DJfTADm_6Dsnx85cZBhjrH6H49udHXCsFoy10k3-bZydMSgLuWCunuJitYRwWfUGlZPWo09O3E3YlBVmRDq01cXT7yTk2lt58ihHaVPjrH8=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.harpoontx.com<\/u><\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \u201clook forward,\u201d \u201cmay,\u201d \u201csuggest,\u201d \u201cexpect,\u201d \u201cpotential,\u201d \u201ccontinued,\u201d \u201cfurther,\u201d \u201cwill,\u201d and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics\u2019 expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics\u2019 clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the expected progress, results, and plans pertaining to Harpoon Therapeutics\u2019 clinical trials and other statements that are not historical fact. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, preliminary data and trends may not be predictive of future data or results,\u00a0may not demonstrate safety or efficacy or lead to regulatory approval by the FDA or other regulatory agencies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, the timing and results of unexpected litigation or other disputes, and the sufficiency of Harpoon Therapeutics\u2019 cash resources. These and other factors that may cause Harpoon Therapeutics\u2019 actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics\u2019 filings with the\u00a0U.S. Securities and Exchange Commission, including under \u201cRisk Factors\u201d in Harpoon Therapeutics\u2019 quarterly report on Form 10-Q for the quarter ended September 30, 2022,\u00a0and future filings by\u00a0Harpoon Therapeutics. Except as required by law,\u00a0Harpoon Therapeutics\u00a0assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>Investors:<br \/>ICR Westwicke<br \/>Robert H. Uhl<br \/>Managing Director<br \/>858-356-5932 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3WVFFu_L1H6p_rm9amNAwkl6WDr9bS8STghhZBKT0CrscbcK98k44sQNVC0v5LpCeWYv1pMHofLetDTSHwiqwvTVBOzsGtQUyZvdnBk5uT4=\" rel=\"nofollow noopener\" target=\"_blank\"><u>robert.uhl@westwicke.com<\/u><\/a><\/p>\n<p>Media:<br \/>Uncapped Communications<br \/>Kerry Walton<br \/>303-588-0599<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wExRcmuTYHJoa0DEhv4i_PgFqumgeEVlmgeDYr1j66sjrZCBvy0EahMTkI-eD62_-8yoJlsPz9HKA-IgYYIgLxxVjw1u-ou_4q6oZCi8mTiyCQ6BjiYH5JOqQ0msF_qRJK3eF12h13128sEpCAC5oA==\" rel=\"nofollow noopener\" target=\"_blank\">kerry.walton@uncappedcommunications.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODQ2MCM1NDYxNzQ3IzIxMjU4MTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MTUyZDU4MzAtMTI0OC00MGQ0LTk3OGMtNmY3ODYwMTA3ODEzLTExMzczODM=\/tiny\/Harpoon-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Preclinical abstracts for investigational T cell engagers, HPN328 and HPN217, in mouse models provide further validation of Harpoon\u2019s proprietary Tri-specific T cell Activating Construct (TriTAC \u00ae ) platform and support ongoing clinical efforts Additional abstracts support further investigation of Harpoon\u2019s conditionally active next-generation T cell engager platform, ProTriTAC\u2122, with demonstrated therapeutic potential in a broad range of TROP2- and ITGB6-expressing solid tumors SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc.\u00a0(Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that it will present data from five preclinical investigations in poster presentations at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Fla., April 14-19, 2023. \u201cThe breadth of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-740110","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Preclinical abstracts for investigational T cell engagers, HPN328 and HPN217, in mouse models provide further validation of Harpoon\u2019s proprietary Tri-specific T cell Activating Construct (TriTAC \u00ae ) platform and support ongoing clinical efforts Additional abstracts support further investigation of Harpoon\u2019s conditionally active next-generation T cell engager platform, ProTriTAC\u2122, with demonstrated therapeutic potential in a broad range of TROP2- and ITGB6-expressing solid tumors SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc.\u00a0(Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that it will present data from five preclinical investigations in poster presentations at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Fla., April 14-19, 2023. \u201cThe breadth of &hellip; Continue reading &quot;Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-14T22:25:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODQ2MCM1NDYxNzQ3IzIxMjU4MTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023\",\"datePublished\":\"2023-03-14T22:25:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\\\/\"},\"wordCount\":975,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODQ2MCM1NDYxNzQ3IzIxMjU4MTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\\\/\",\"name\":\"Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODQ2MCM1NDYxNzQ3IzIxMjU4MTI=\",\"datePublished\":\"2023-03-14T22:25:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODQ2MCM1NDYxNzQ3IzIxMjU4MTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODQ2MCM1NDYxNzQ3IzIxMjU4MTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/","og_locale":"en_US","og_type":"article","og_title":"Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023 - Market Newsdesk","og_description":"Preclinical abstracts for investigational T cell engagers, HPN328 and HPN217, in mouse models provide further validation of Harpoon\u2019s proprietary Tri-specific T cell Activating Construct (TriTAC \u00ae ) platform and support ongoing clinical efforts Additional abstracts support further investigation of Harpoon\u2019s conditionally active next-generation T cell engager platform, ProTriTAC\u2122, with demonstrated therapeutic potential in a broad range of TROP2- and ITGB6-expressing solid tumors SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc.\u00a0(Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that it will present data from five preclinical investigations in poster presentations at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Fla., April 14-19, 2023. \u201cThe breadth of &hellip; Continue reading \"Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-14T22:25:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODQ2MCM1NDYxNzQ3IzIxMjU4MTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023","datePublished":"2023-03-14T22:25:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/"},"wordCount":975,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODQ2MCM1NDYxNzQ3IzIxMjU4MTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/","name":"Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODQ2MCM1NDYxNzQ3IzIxMjU4MTI=","datePublished":"2023-03-14T22:25:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODQ2MCM1NDYxNzQ3IzIxMjU4MTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODQ2MCM1NDYxNzQ3IzIxMjU4MTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-acceptance-of-five-abstracts-for-presentation-at-aacr-annual-meeting-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=740110"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740110\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=740110"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=740110"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=740110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}